Literature DB >> 2065889

Prospects for an HIV-vaccine.

H Wigzell1.   

Abstract

A vaccine against HIV is badly needed. In the average clinical situation the virus displays a low-rate capacity to transfer infection. The frequency is significantly below 1 per contact situation, that is, a single infectious unit is the normal cause of infection. The time to induce disease in the adult is between 5 and 10 years. These facts are considered positive in relation to producing an HIV vaccine to achieve sterilizing and/or protective immunity. A summary of animal and human HIV/SIV vaccine studies is made giving certain support for the prospects of producing an HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2065889     DOI: 10.1096/fasebj.5.10.2065889

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  3 in total

1.  Pattern of gp120 sequence divergence linked to a lack of clinical progression in human immunodeficiency virus type 1 infection.

Authors:  W K Wang; M Essex; M F McLane; K H Mayer; C C Hsieh; H G Brumblay; G Seage; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

2.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.

Authors:  C J Miller; M B McChesney; X Lü; P J Dailey; C Chutkowski; D Lu; P Brosio; B Roberts; Y Lu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.

Authors:  G Baier; G Baier-Bitterlich; D J Looney; A Altman
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.